Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-23T04:21:40.889Z Has data issue: false hasContentIssue false
  • English
  • Français

Progress in Neurotherapeutics and Neuropsychopharmacology 2007

Published online by Cambridge University Press:  19 May 2006

Jeffrey L. Cummings
Jeffrey L. Cummings
Affiliation:
Deane F. Johnson Center for Neurotherapeutics at UCLA; UCLA Alzheimer Disease Center, Augustus Rose Professor of Neurology, Professor of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Extract

ABSTRACT

There continues to be progress in neurotherapeutics and neuropsychopharmacology with each advancing year. Production of new molecular entities (NME's) remains small, but advances are being made in repurposing agents and extending their indications, obtaining more safety and tolerability data in long term and extension studies, introducing novel trial methodologies that provide insight into how to best to conduct trials and how best to treat diseases, and developing new formulations that improve adherence and decrease the barriers to patient compliance. Advances in how to test potential disease-modifying agents in patients with progressive neurological illnesses is advancing. Promising biomarkers have been identified in some neurological diseases.

Keywords

Clinical trialsdrug developmentfutility trialsParkinson's diseaseAmyotrophic Lateral SclerosisSchizophrenia
Type
Review Article
Information
Progress in Neurotherapeutics and Neuropsychopharmacology , Volume 2 , Issue 1 , March 2007 , pp. 1 - 12
Copyright
© 2007 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Babic, T., Boothmann, B., Polivka, J., et al. (2006). Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study. Clinical Neuropharmacology, 29, 238–242.Google Scholar
Barkhof, F., Held, U., Simon, J.H., et al. (2005). Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. Neurology, 65, 1447–1454.Google Scholar
Bender, S., Dittmann-Balcar, A., Schall, U., et al. (2006). Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. International Journal of Neuropsychopharmacol, 9, 135–145.Google Scholar
Cree, B.A., Al-Sabbagh, A., Bennett, R., et al. (2005). Response to interferon beta-1a treatment in African American multiple sclerosis patients. Archives of Neurology, 62, 1681–1683.Google Scholar
Cudkowicz, M.E., Shefner, J.M., Schoenfeld, D.A., et al. (2006). Trial of celecoxib in amyotrophic lateral sclerosis. Annals of Neurology, 60, 22–31.Google Scholar
Cummings, J.L. (2006). What we can learn from open-label extensions of randomized clinical trials. Archives of Neurology, 63, 18–19.Google Scholar
Cummings, J.L. (2006). Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimer's and Dementia, 67, 726–727.Google Scholar
de Carvalho, M., & Swash, M. (2006). Can selection of rapidly progressing patients shorten clinical trials in amyotropic lateral sclerosis? Archives of Neurology, 63, 557–560.Google Scholar
de Tommaso, M., Di Fruscolo, O., Sciruicchio, V., et al. (2005). Efficacy of levetiracetam in Huntington disease. Clinical Neuropharmacology, 28, 280–284.Google Scholar
Dowling, G.A., Mastick, J., Colling, E., et al. (2005). Melatonin for sleep disturbances in Parkinson's disease. Sleep Medicine, 6, 459–466.Google Scholar
Elger, C.E., Brodie, M.J., Anhut, H., et al. (2005). Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia, 46, 1926–1936.Google Scholar
Emre, M., Aarsland, D., Albanese, A., et al. (2004). Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine, 351, 2509–2518.Google Scholar
Johnston, S.C. (2006). Translation: case study in failure. Annals of Neurology, 59, 447–448.Google Scholar
Kappos, L., Antel, J., Comi, G., et al. (2006). Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine, 355, 1124–1140.Google Scholar
Kemmler, G., Hummer, M., Widschwendter, C., et al. (2005). Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Archives of General Psychiatry, 62, 1305–1312.Google Scholar
Kim, S.Y., Holloway, R.G., Frank, S., et al. (2006). Volunteering for early phase gene transfer research in Parkinson disease. Neurology, 66, 1010–1015.Google Scholar
Lane, H.Y., Chang, Y.C., Liu, Y.C., et al. (2005). Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Archives of General Psychiatry, 62, 1196–1204.Google Scholar
Lang, A.E, Gill, S., Patel, N.K., et al. (2006). Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Annals of Neurology, 59, 459–466.Google Scholar
Lees, K.R., Zivin, J.A., Ashwood, T., et al. (2006). NXY-059 for acute ischemic stroke. New England Journal of Medicine, 354, 588–600.Google Scholar
Markus, H.S., Droste, D.W., Kaps, M., et al. (2005). Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation, 111, 2233–2240.Google Scholar
Massacesi, L., Parigi, A., Barilaro, A., et al. (2005). Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Archives of Neurology, 62, 1843–1847.Google Scholar
Mathew, S.J., Amiel, J.M., Coplan, J.D., et al. (2005). Open-label trial of riluzole in generalized anxiety disorder. American Journal of Psychiatry, 162, 2379–2381.Google Scholar
Mayer, S.A., Brun, N.C., Begtrup, K., et al. (2005). Recombinant activated factor VII for acute intracerebral hemorrhage. New England Journal of Medicine, 352, 777–785.Google Scholar
Molyneux, A.J., Kerr, R.S., Yu, L.M., et al. (2005). International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet, 366, 809–817.Google Scholar
Montgomery, S.A., Tobias, K., Zornberg, G.L., et al. (2006). Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. Journal of Clinical Psychiatry, 67, 771–782.Google Scholar
Ondo, W.G., Fayle, R., Atassi, F., et al. (2005). Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. Journal of Neurology Neurosurgery and Psychiatry, 76, 1636–1639.Google Scholar
O'Reardon, J.P., Allison, K.C., Martino, N.S., et al. (2006). A randomized, placebo-controlled trial of sertraline in the treatment of night eating syndrome. American Journal of Psychiatry, 163, 893–898.Google Scholar
Palesch, Y.Y., Tilley, B.C., Sackett, D.L., et al. (2005). Applying a phase II futility study design to therapeutic stroke trials. Stroke, 36, 2410–2414.Google Scholar
Palhagen, S., Heinonen, E., Hagglund, J., et al. (2006). Selegiline slows the progression of the symptoms of Parkinson disease. Neurology, 66, 1200–1206.Google Scholar
Reisberg, B., Doody, R., Stoffler, A., et al. (2006). A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Archives of Neurology, 63, 49–54.Google Scholar
Rockwood, K., Fay, S., Song, X., et al. (2006). Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. CMAJ, 174, 1099–1105.Google Scholar
Simpson, H.B., Huppert, J.D., Petkova, E., et al. (2006). Response versus remission in obsessive–compulsive disorder. Journal of Clinical Psychiatry, 67, 269–276.Google Scholar
The Parkinson Study Group* (2006). Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. Neurology, 66, 408–410.Google Scholar
Winblad, B., Kilander, L., Eriksson, S., et al. (2006). Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet, 367, 1057–1065.Google Scholar